· Dresden 2006 - Vom Nihilismus zum Algorithmus ·

Myelodysplastische Syndrome: Therapiestrategien aus Sicht der evidenzbasierten Medizin

Autor: Priv.-Doz. Dr. med. Axel Glasmacher, Celgene GmbH, München

Quellenangabe: Deutsches MDS-Forum - Dresden 2006

Stand: 27.11.2006

Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Blood 2004;104:579-85. PM:15039286
[Medline]
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J.
International scoring system for evaluating prognosis in myelodysplastic syndromes
Blood 1997;89:2079-88. PM:9058730
[Medline]
Greenberg PL, Young NS, Gattermann N.
Myelodysplastic syndromes.
Hematology Am Soc Hematol Educ Program 2002;136-161. PM:12446422
[Medline]
Giagounidis AA, Germing U, Aul C.
Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
Clin Cancer Res 2006;12:5-10. PM:16397017
[Medline]
Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C.
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Ann Hematol 2005;84:569-571. PM:15891887
[Medline]
Antes A, Bassler D, Forster J.
Evidenz-basierte Medizin.
Praxis-Handbuch für Verständnis und Anwendung der EBM. Thieme: 2003.